Yildiz, Bulent Okan http://orcid.org/0000-0003-1797-7662
Boguszewski, Cesar Luiz
da Silva Boguszewski, Margaret Cristina
Busetto, Luca
Celik, Ozlem
Fuleihan, Ghada El-Hajj
Goulis, Dimitrios G.
Hammer, Gary D.
Haymart, Megan R.
Kaltsas, Gregory
Law, Jennifer R.
Lim, Amanda Yuan Ling
Luger, Anton
Macut, Djuro
McGowan, Barbara
McClung, Michael
Miras, Alexander Dimitri
Patti, Mary Elizabeth
Peeters, Robin P.
Pignatelli, Duarte
Saeed, Hamayle
Sipos, Jennifer
Stratakis, Constantine A.
Tsoli, Marina
van der Lely, A. J.
Witchel, Selma F.
Yazici, Dilek
Article History
Received: 22 February 2024
Accepted: 6 March 2024
First Online: 15 April 2024
Declarations
:
: B.O.Y., O.C., D.G.G, M.R.H., J.R.L., A.Y.L.L., D.M., M.E.P., R.P.P., D.P., H.S., J.S., S.F.W., D.Y. have no relevant disclosures to report. C.L.B. has received consultant/speaker fees from Novo Nordisk, Recordati and Ipsen; participated as clinical investigator in international multicentric trials of Crinetics. M.C.D.B. has received consultant/speaker fees from Novo Nordisk and Pfizer. L.B. has received honoraria for lectures from Rhythm Pharmaceuticals and PronoKal as well as payment of honoraria for attendance to advisory boards from Lilly, Pfizer, Bruno Farmaceutici, and Novo Nordisk. G.E.F. has received travel support from Abiogen. G.D.H. is the founder of Millendo Therapeutics. G.K. has received honoraria from Ipsen, Sanofi, Recordati and research funds from Ipsen, Recordati, FARAN and Pfizer. A.L. has received consulting fees from Novo Nordisk, Boehringer Ingelheim, Eli Lilly, Novartis, Novo Nordisk and Sanofi. B.M. is a shareholder and board member of Reset Health, has received advisory fees from Novonordisk, J&J Ethicon, Lilly, fees for educational work from Lilly, Novonordisk, BI, Janssen, MSD, Sanofi, Astra Zeneca, institutional research grant support from Novonordisk. M.M. has received honoraria for speaking and consulting fees from Amgen and honoraria for speaking from UCB and Alexion. M.M. is a member of the Boards of the International Osteoporosis Foundation and the American Society of Osteoporosis Practitioners and just completed a 6-year term as a Board member of the North American Menopause Society. A.D.M. has received research funding from the MRC, NIHR, Jon Moulton Charitable Foundation, Fractyl, Gila, Randox and Novo Nordisk. A.D.M. is a shareholder in the Beyond BMI clinic, which provides clinical obesity care. C.A.S. serves as a consultant to ELPEN, SteroTx, and Lundbeck pharmaceuticals; has received a research grant from Pfizer for the study and treatment of acromegaly; and holds patents on the defects and function of the PRKAR1A, PDE11A, and GPR101 genes. M.T. has received honoraria from Ipsen and FARAN. A.J.vdL has received consultancy fees or speakers fee of Amolyt Pharma SA, Crinetics Inc and Ipsen Pharma.